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The capability of cellular immune components to rapidly recall upon challenge in most situations decides the efficacy of a vaccine. Here,
we show that immunization of mice with SSIEFARL peptide (immunodominant epitope in glycoprotein B of herpes simplex virus type 1,
aa498-505) combined with TLR9 ligand in the absence of helper CD4+ T cell activation generates a functionally impaired CD8+ T cell
memory response. Codelivery of IL-12, IL-15, or anti-CD40 together with MHC class-I-restricted peptide combined with TLR9 ligand at
inception of immunization resulted in generation of memory CD8+ T cells that were several fold less compromised than immunization with
peptide alone. Furthermore, administration of either plasmid DNA encoding IL-15 or anti-CD40 mAb but not rIL-12 during the memory
phase restored the reactivity of memory CD8+ T cells. Moreover, the rescued CD8+ T cells preserved their cytotoxic capability and were able
to clear a recombinant vaccinia virus encoding glycoprotein B of HSV. Our results indicate that good memory CD8+ T cell response to
peptide immunization can be achieved by using costimulatory procedures at the time of priming or recall immunization.
D 2004 Elsevier Inc. All rights reserved.
Keywords: Herpes simplex virus; TLR9 ligand; IL-12; IL-15; Anti-CD40 mAb; Memory CD8+ T cellsIntroduction
Several studies have shown that CD8+ T cell responses
occur normally in the absence of CD4+ helper cell costimu-
lation, but the generation of the memory CD8+ Tcell response
is compromised (Bourgeois et al., 2002; Janssen et al., 2003).
However, others suggest that CD4+ helper T cell costimula-
tion is also required for the development of a primary immune
response (Wang and Livingstone, 2003). Studies with murine
models of chronic viral infections show that CD4+ T cells are
essential formaintaining CD8+CTL responses (Shedlock and
Shen, 2003; Sun and Bevan, 2003) and in humans there is a
correlation between the decline of CD4+ T cells and loss of
HIV-specific CD8+ Tcell responses during the progression of0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.10.022
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E-mail address: btr@utk.edu (B.T. Rouse).AIDS (Kostense et al., 2002). In the vaccination setting,
CD8+ T cells raised in the absence of CD4+ T cell help are
functionally aberrant and remain CD62Llow, CD44int, and
CD122low (Khanolkar et al., 2004). The help provided by
CD4+ T cells is mediated by CD40–CD154 interaction,
which is said to condition antigen presenting cells for
effective activation of CD8+ T cells (Ninomiya et al.,
2002). Alternatively, there may be a direct action of CD40
on the responding CD8+ T cells (Khanolkar et al., 2004;
Lefrancois et al., 1999). Whichever mechanism is involved,
the critical outcome for vaccine design is the generation of
CD8+ T cell response that is effective and durable.
The CD8+ T cell responses generated in the absence of
effective help may function effectively in the primary phase
but deficiencies become evident in the memory response.
However, if these memory cells are treated with interleukin 2
(IL-2) in vitro during restimulation, they recover their05) 151–158
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comprised memory immune response can be rescued in vivo
by providing other forms of stimulus at the priming stage or
later in the memory stage. Our previous study (Gierynska et
al., 2002) showed that mice immunized with an immunodo-
minant epitope derived from HSV glycoprotein B (aa 498–
505; SSIEFARL) combined with toll like receptor 9 ligand
(TLR9 ligand, CpG1826), generated antigen-specific CD8+
T cells. This immune response protected against a vaginal
HSV challenge in the primary phase. However, when mice
were challenged vaginally or systemically in the memory
phase, they succumbed to infection after a brief delay of
clinical signs. Accordingly, our results showed that SSIE-
FARL/TLR9 ligand mixture can induce CD8+ T cell
immunity, but this immunity deteriorated with time and
was functionally ineffective. The population of memory
CD8+/IFNg+ cells also decreased indicating that other
factors are required for maintaining the memory pool of
protective CTLs. Therefore, this study examined various
pathways of restoring and maintaining the functionality of
memory CD8+ T cells derived from immunization with
MHC class-I-restricted peptide combined with TLR9 ligand.
Accordingly, we substituted the CD4 help with recombinant
IL-12 (rIL-12), plasmid encoding IL-15 (pIL-15), or anti-
CD40 mAb administration.
IL-12 modulates the CTL response and allows potent
selective proliferation of CD44hi CD8+ Tcells in vivo (Zhang
et al., 1998) (reviewed in Toka et al., 2004). IL-15 is said to
maintain the homeostasis of memory CD8+ T cells (Berard et
al., 2003) and overexpression of IL-15 in vivo increased
antigen-driven memory CD8+ T cells after exposure to
antigen (Yajima et al., 2002). CD40 is expressed on antigen
presenting cells and CD4+ Tcells as a costimulatory molecule
and is up-regulated upon activation with microbial products
or virus infection. The CD40–CD40L interaction induces a
productive CD8+ T cell response (Lefrancois et al., 2000).
Results described in this study show that the defective
memory CD8+ T cell responses generated by immunization
with TLR9 ligand/SSIEFARL could be rescued by provision
of rIL-12, pIL-I5, or anti-CD40 mAb.Results
Previously (Gierynska et al., 2002), it was shown that the
antigen-specific CD8+ T cell memory generated by immu-
nizing mice with SSIEFARL/TLR9 ligand waned with time.
We considered three pathways to extend the duration of
CD8+ T cell memory responses upon vaccination with
SSIEFARL peptide combined with TLR9 ligand.
IL-15 enhances memory CD8+ T cell immune response
against HSV-1
C57BL/6 mice were immunized with SSIEFARL + TLR9
ligand or control CpG1982 + SSIEFARL, and pIL-15 wasgiven 2 weeks postsecondary immunization. Mice immu-
nized with SSIEFARL + TLR9 ligand or control CpG1982 +
SSIEFARL and then inoculated with ph-gal served as control
animals. Analysis of memory Tcell retention was done at day
60 postsecondary immunization. The results are summarized
in Fig 1. First, the CD8+ T cell response, measured by
peptide-induced intracellular IFN-g production, was evident
only in mice immunized with TLR9 ligand plus SSIEFARL
(Fig. 1A). Second, the use of pIL-15 at memory phase in mice
vaccinated with SSIEFARL + TLR9 ligand increased the
number of IFN-g producing CD8+ T cells almost threefold
compared with the group vaccinated without pIL-15 and
other negative controls (data not shown). Administration of
pIL-15 to mice immunized with control CpG1982 +
SSIEFARL did not lead to the generation of CD8+/IFNg+ T
cells. A similar pattern of events was evident when results
were measured by the CTL assay (Fig. 1B). These data show
that administration of pIL-15 enhanced and helped maintain
the level of antigen-specific CD8+ T cell memory population
after peptide vaccination.
IL-12 or anti-CD40 can rescue the CD8+ T cell memory
response generated with peptide immunization
Two other strategies were tested to assess the possibility of
generating a durable memory response after peptide immu-
nization. rIL-12 (i.m.) or anti-CD40 mAb (i.p.) was
coadministered with TLR9 ligand/SSIEFARL. Primary
immune responses are summarized in Figs. 2A and B.
Memory responses after anti-CD40 coadministration were
measured 60 days postimmunization. In the spleen, the
memory IFN-g producing CD8+ T cells were fivefold higher
in agonistic antibody-treated mice compared to nontreated
mice (Fig. 2C). LN memory CD8+ T cell response, although
low, was detectable and above the levels detected in non-anti-
CD40-injected mice. Injection of rIL-12 showed a similar
pattern of responses but only a 1.5-fold high memory CD8+ T
cell reactivity was detected compared with mice immunized
without rIL-12 (Fig. 2D). Taken together, IL-12 induced a
memory CD8+ T cell population that was not more
compromised, but anti-CD40 administered at inception of
immunization allowed generation of higher CD8+ T cell
memory in the absence of activated CD4 T cells.
It was necessary to determine whether application of the
reactivating stimulus later in the memory phase following
SSIEFARL/TLR9 ligand immunization would correct the
memory CD8+ T cells functional deficiency. To investigate
this possibility, animals were vaccinated with SSIEFARL
combined with TLR9 ligand. At least 60 days later,
vaccinated mice were treated with anti-CD40 mAb or rIL-
12 alone without antigen. As expected, mice that did not
receive any stimulus in the memory phase showed no
reactivity of the memory CD8+ T cells upon restimulation
in vitro (Fig. 3a) and were comparable to isotype IgG-treated
mice (Fig. 3b). A similar pattern of response was shown for
rIL-12-treated mice (Fig. 3c), that is, no expansion of
Fig. 1. Influence of plasmid DNA encoded IL-15 on maintenance of HSV-specific CD8+ T cells. C57BL/6 mice were immunized twice (days 0 and 7) with
SSIEFARL combined with TLR9 ligand (TLR9L) or control CpG 1982. Two weeks postsecondary immunization mice were inoculated with 50 Ag of pIL-15.
Memory immune responses were assessed at 60 days from initial immunization. (A) Influence of pIL-15 on SSIEFARL-specific CTL precursors. The lytic
activity against MC38 cells pulsed with SSIEFARL was scored in a standard 51Cr release assay. Controls, included but not shown, were MHC mismatched or
irrelevant peptide targets. (Ai) shows absolute numbers of IFN-g-producing CD8+ T cells. Means F SE, *P V 0.05 in comparison to h-gal and control. (B)
Functional analysis of SSIEFARL-specific CD8+/IFNg+ cells isolated from mice inoculated with pIL-15. The cells were stimulated with 1 Ag of SSIEFARL/
106 cells in the presence of Brefeldin A and 50U of IL-2/100 ml for 5 h. The figure shows analysis of the splenocytes gated on CD8+ T cells. Each experimental
group contained four animals and the data presented were derived from two independent experiments.
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in the memory phase. In contrast, mice given anti-CD40mAb
in the memory phase expanded the antigen-specific memory
CD8+ T cell population resulting in a threefold increase
compared with non-anti-CD40 mAb-treated mice (Fig. 3d).
In another experiment, mice were boosted with SSIEFARL
and codelivery of rIL-12 or anti-CD40 mAb. rIL-12 given
together with SSIEFARL/TLR9 ligand did not expand IFN-g
producing SSIEFARL-specific CD8+ T cells (Fig. 3e),
whereas anti-CD40 led to a vigorous expansion of SSIE-
FARL-specific CD8+ T cells (eightfold IFN-g production by
ELISPOT) in comparison to mice treated isotype Ig or no
antibody (Fig. 3e). These results suggest that application of
anti-CD40 but not IL-12 in the memory phase can correct the
reactivity of antigen-specific memory CD8+ Tcells generated
earlier by MHC class-I-restricted peptide immunization.
Moreover, expansion of the memory CD8+ T cells and
improvement of their function induced by anti-CD40 were
antigen independent.A functional CD8+ T cell should lyse a target cell
expressing cognate antigen. To determine if these CD8+ T
cells, expanded by administration of anti-CD40, were func-
tional CTLs, a conventional 51Cr release assay was
performed. Surprisingly, the cytolytic capability of these
memory CD8+ T cells was preserved upon administration of
anti-CD40 mAb but not rIL-12 compared to nontreated mice
(Fig. 3f). The data demonstrate that anti-CD40 and can rescue
the lytic activity of CD8+ T cells previously generated in the
absence of CD4+ T helper cells.
Rescued memory CD8+ T cells are able to clear virus
efficiently
To find out if the rescued memory CD8+ T cells from
mice immunized earlier with SSIEFARL/TLR9 ligand and
injected with pIL-15, rIL-12, or anti-CD40, animals were
challenged with recombinant vaccinia virus encoding gB
of HSV. Virus titers are summarized in Tables 1 and 2. At
Fig. 2. Effect of IL-12 or anti-CD40 on the magnitude of primary and
memory immune response in SSIEFARL/TLR9 ligand immunized mice.
Mice were immunized with either SSIEFARL/TLR9 ligand together with
IL-12 or anti-CD40 antibody. Control mice were injected with nonbioactive
CpG 2138 or isotype IgG. Primary immune responses were determined at
7 days postimmunization and memory responses were analyzed at 60 days.
(A and B) Primary IFN-g ELISPOT for IL-12 and anti-CD40-treated mice,
respectively. (C and D) Memory responses of IL-12 or anti-CD40-treated
mice, respectively. Each experimental group contained four animals and
the data presented were derived from two independent experiments. *P V
0.05. Data are presented as means F SE.
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efficiently cleared the virus by day 7 with a log difference
of 3 compared with nontreated mice. In contrast, rIL-12
had a lower clearance of virus because only 1.7 log
difference was evident by day 7. At high dose of virus
mice injected with rIL-12 did not clear the challenge virus,
whereas pIL-15 and anti-CD40-treated mice partially
cleared the virus by day 7 with, respectively, a 1.3 and
1.2 log difference compared to nontreated mice. Taken
together, the restoration of memory CD8+ T cells reactivity
also preserved the CTL activity of these cells.Discussion
In this study, we show that peptide vaccination against
HSV-1 leads to the generation of a functionally impaired
CD8+ Tcell memory response due to the lack of the activation
of helper CD4+ Tcells. Codelivery of rIL-12, pIL-15, or anti-
CD40 together with SSIEFARL combined with TLR9 ligand
at the inception of immunization resulted in the generation of
memory CD8+ T cells that were several fold higher than
immunization with peptide alone. Administration of either
pIL-15 or anti-CD40 mAb, but not rIL-12, during the
memory phase rescued the reactivity of memory CD8+ T
cells. Moreover, the rescued CD8+ T cells preserved their
cytotoxic capability and cleared a recombinant vaccinia virus
encoding glycoprotein B of HSV-1. The data imply that
peptide immunization based on MHC class-I-restricted
epitopes alone may not be optimum for eliciting an effective
CD8+ Tcell memory immune response. Codelivery of IL-12,
IL-15, or an agonist mAb against CD40 as well as appropriate
timing of delivery of these reagents may induce long-term
CD8+ T cell memory.
Events that occur at the priming of effector T cell response
are critical to the generation and maintenance of memory
responses. CD4+ Tcell help plays a vital role in the generation
of a functional CD8+ T cell memory response (Belz et al.,
2002; Kurts et al., 1997). Immunization of CD4-deficient
mice with syngeneic human adenovirus type 5 E1-trans-
formed Tap/ mouse embryo cells abrogated generation of
E1B (192–200) peptide-specific cytotoxic T cells after
secondary in vitro stimulation (Janssen et al., 2003). Similar
studies by Shedlock and Shen (2003) and Sun and Bevan
(2003) reported that CD4/ and MHC class II/ mice,
respectively, mounted defective secondary CD8+ T cells
responses. In all the three studies, mice become vulnerable to
infection in the memory phase, indicating that the CD4+ T
cells were required for memory cell differentiation (Masopust
et al., 2004). Our results coincide with these reports and show
that immunization with only MHC class-I-restricted HSV-1
peptide generates an inferior CD8+ T cell memory response.
Significantly, our study shows that vaccinating with such a
peptide combined with TLR9 ligand, and codelivery of rIL-
12, pIL-15, or anti-CD40 mAb, rescues CD8+ T cell memory
response.
Fig. 3. Anti-CD40 treatment in memory phase expands SSIEFARL-specific CD8+ T cell response. Animals were immunized with SSIEFARL peptide and
TLR9 ligand or nonbioactive CpG2138 for negative controls. At least 60 days later, mice were given (i) rIL-12 or anti-CD40 alone or (ii) IL-12 or anti-CD40
with SSIEFARL peptide. Responses were determined 7 days later by intracellular staining or ELISPOT for IFN-g production by SSIEFARL-specific CD8+ T
cells. (a) SS-TLR9 ligand; (b) Iso_IgG; (c) rIL-12 or (d) anti-CD40 alone; (e) ELISPOT for rIL-12 or anti-CD40 with peptide. Data presented as means F SD,
*P V 0.05; (f) CTL-spleen cells were collected from mice immunized with SSIEFARL + TLR9 ligand and injected with rIL-12 or anti-CD40. A standard 51Cr
release assay was performed after 5 days in vitro expansion with peptide pulsed, X-irradiated bulk splenocytes. Each experimental group contained four
animals and the data presented were derived from two independent experiments.
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on CD8+ T cells leading to induction of a signal that
endows these cells with memory properties. Others
(Chang et al., 2004; Curtsinger et al., 2003; Schmidt
and Mescher, 2002) have shown the direct interaction of
IL-12 and CD8+ T cells, which occurs only when IL-12 is
coadministered with antigen at the priming stage. Appli-
cation of IL-12 to memory T cells did not enhance their
reactivity (Curtsinger et al., 2003; Schmidt and Mescher,
2002). Similarly, in our study, injection of IL-12 at the
memory stage did not enhance the performance of
memory CD8+ T cells. Therefore, exogenous IL-12 may
compensate for signals provided by CD4+ T helper cells
and induce memory CD8+ T cells in MHC class-I-
restricted peptide immunization.Table 1
Mean log10 titers of virus in the ovaries collected at days 3 and 7 following
challenge with 1  105 pfu/mouse vaccinia virus gB
Group Day 3 Day 7
h-gal 4.09 F 0.98 3.17 F 0.87
Iso_IgG 4.11 F 0.21 3.89 F 0.78
SS-CpG1826 3.73 F 0.91 3.03 F 0.19
SS-CpG1826 + IL-12 2.21 F 0.40 1.8 F 0.98
SS-CpG1826 + IL-15 1.02 F 0.16 0.92 F 0.54
SS-CpG1826 + anti-CD40 1.37 F 1.1 0.87 F 0.19
The values represent F SD of four mice per group in two separate
experiments.Memory T cells do not require the MHC–peptide
interaction for maintenance (Lodolce et al., 1998; Murali-
Krishna et al., 1999; Swain et al., 1999). Therefore,
cytokines may drive the survival of memory CD8+ T cells
and IL-15 appears suitable for this task. IL-15 induces Bcl-2
expression responsible for the inhibition of apoptosis in
activated CD8+ T cells (Berard et al., 2003; Giri et al., 1994),
thus maintaining the numbers of memory T cells. Selective
stimulation of CD8+ T cells by IL-15 was observed when IL-
15 was injected in mice that were later given BrdU (Zhang et
al., 1998). In these studies, only the CD44hi/CD8+ Tcells and
not CD4+ T cells markedly increased BrdU labeling,
indicating that the selective action of IL-15 is on memory
CD8+ T cells. In our study, the role of IL-15 in supporting the
maintenance of memory T cells was evident at the level ofTable 2
Mean log10 titers of virus in the ovaries collected at days 3 and 7 following
challenge with 1  107 pfu/mouse vaccinia virus gB
Group Day 3 Day 7
h-gal 4.96 F 0.46 nd
Iso_IgG 4.97 F 0.11 nd
SS-CpG1826 4.51 F 1.5 4.21 F 0.22
SS-CpG1826 + IL-12 4.72 F 0.96 4.65 F 0.18
SS-CpG1826 + IL-15 3.90 F 0.19 3.69 F 0.65
SS-CpG1826 + anti-CD40 3.01 F 1.5 3.53 F 0.12
The values represent F SD of four mice per group in two separate
experiments; nd—not done.
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clearly outnumbered those detected in mice not given IL-15
plasmid DNA. The fact that pIL-15 could maintain CD8+ T
cell numbers in vaccinated mice indicated that one of the
deficiencies of the CD8+ T cells in mice not given pIL-15
likely affects the IL-15 signaling pathway. Our results
demonstrate that IL-15 can be applied in immunization
together with a class-I-restricted peptide to maintain a
functional pool of memory CD8+ T cells in vivo.
CD40–CD40 ligand interaction plays a critical role in the
provision of help for CTL generation (Sarawar et al., 2001;
Schoenberger et al., 1998). We administered anti-CD40 mAb
together with peptide and TLR9 ligand and assessed the
outcome of the memory immune response. Indeed our studies
confirm the finding of several others (Ahonen et al., 2004;
Lefrancois et al., 1999, 2000; Sarawar et al., 2001;
Schoenberger et al., 1998) and show that cotriggering of
TLR9 and CD40 can replace the CD4+ T cell helper function
in eliciting a strong memory CD8+ T cell immune response.
According to Koschella et al. (2004), this action of anti-CD40
is directed at memory Tcells because there was no conversion
of CD44low to CD44hi CD8+ T cells after administration of
anti-CD40, only CD44hi increased due to proliferative
response. However, the possibility that anti-CD40 could act
directly on CD8+ T cells was discounted since CD8+ T cells
transferred into CD40-deficient mice did not proliferate
following injection of anti-CD40 mAb (Koschella et al.,
2004). Therefore, activation of memory CD8+ T cells may be
mediated through the activation of antigen presenting cells. In
our system, administration of anti-CD40 mAb led to increase
in the production of IFN-g indicating a possible increase in
the number of antigen-specific T cells in agreement with the
work described by Schoenberger et al. (1998). Furthermore,
administration of the TLR9 ligand and anti-CD40 appeared to
have induced a synergistic increase in the generation of HSV-
specific CD8+ T cells and their transition into memory CD8+
T cells, suggesting that combination of a TLR and CD40
costimulation may maximize the immune response to a
peptide based vaccine against HSV-1. This effect is similar to
that reported by Ahonen et al. (2004) using OVA-specific T
cells.
One study examined the influence of anti-CD40 on
generation of immune response to an influenza NP antigen
(Ninomiya et al., 2002). Strong immune response was
generated in the primary phase but memory responses were
drastically reduced. This contrasts our finding in which we
noted a high level of memory response. One possible
explanation for the difference between the two studies could
be the dose and frequency of anti-CD40 administration.
Ninomiya et al. (2002) injected anti-CD40 on three occasions
at a dose of 250 Ag/mouse while we administered a single
dose at 100 Ag/mouse. Repeated administration of the anti-
CD40 mAb leads to T cell tolerization or deletion of antigen-
specific T cells (Geiger et al., 1993; Kedl et al., 2001). This
means that the dosage and frequency of anti-CD40 injection
in a vaccination protocol require careful study.In conclusion, the requirement for CD4+ T cell help in
MHC class-I-restricted peptide immunization against HSV-1
can be fulfilled by provision of rIL-12, pIL-15, or agonistic
anti-CD40 mAb. Such codelivery together with peptide/
TLR9 ligand in the vaccination regimen leads to rescue and
preservation of SSIEFARL-specific memory CD8+ T cells.
Although administration of rIL-12, pIL-15, or anti-CD40
mAb led to rescue of memory CD8+ T cell ability to produce
IFN-g and CTL activity and subsequent clearance of
recombinant virus, we still have yet to assess if the these
cells can effectively control challenge with a native virus in
vivo, preferably in an adoptive transfer model.Materials and methods
Mice
Female C57BL/6 mice (6 weeks old) were purchased from
Harlan Sprague–Dawley (Indianapolis, IN). In conducting
the research described in this work, the investigators adhered
to institutional guidelines on animal care and use.
Reagents
CpG oligonucleotides: bioactive CpG 1826 (5V-
TCCATGACGTTCCTGACGTT-3V) referred to throughout
this work as TLR9 ligand, control CpG 1982 (5V-
TCCAGGACTTCTCTCAGGTT-3V) were purchased from
Coley Pharmaceutical Group (Wellesley, MA) and had
undetectable endotoxin levels. MHC class-I-restricted
HSV-1 gB498–505 (SSIEFARL) was synthesized by Gen-
emed Synthesis, Inc. (South San Francisco, CA). The
plasmid encoding IL-15 was a kind gift from Dr. Kenji
Okuda (Department of Bacteriology, Yokohama City
University School of Medicine, Yokohama, Japan) (Xin
et al., 1999). The plasmid encoding h-galactosidase (h-gal)
was purchased from Clontech (Palo Alto, CA). Mono-
clonal antibodies against murine IFN-g and CD8 were
purchased from BD Pharmingen (San Diego, CA).
Plasmid DNA preparation
Plasmid DNA encoding IL-15 or h-galactosidase was
purified by polyethylene glycol precipitation as described
earlier (Eo et al., 2001a, 2001b). The quality of DNA was
checked by electrophoresis on 1% agarose gel (data not
shown).
Immunization
In all experiments, C57BL/6 mice were immunized with
100 Ag of SSIEFARL combined with 30 Ag of TLR9 ligand
or control CpG 1982 or 2138. Immunogens were introduced
in the hind footpads (f.p.) twice on days 0 and 7, and
immune response was assessed 7 days later (acute phase) or
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maintaining CD8+ T cell memory, peptide-immunized
C57BL/6 mice were inoculated intramuscularly (i.m.) with
50 Ag of pIL-15 2 weeks postsecond immunization. To
assess the role of rIL-12 or anti-CD40 (clone FGK45) on the
level of memory generated following peptide immunization,
2 ng/mouse, rIL-12 was administered together with SSIE-
FARL + TLR9 ligand into the footpad, while anti-CD40 was
given intraperitoneally at a dose of 100 Ag/mouse at the
same time as the vaccine.
51Cr release assay
Cells isolated from the DLN and spleens of immunized or
control mice were first expanded in vitro by incubating
responder and stimulator cells pulsed with peptide for 5 days
in 378C and 5% CO2. The
51Cr release assay was performed
as described previously (Gierynska et al., 2002).
Quantification of IFNc-producing cells
ELISPOT assay was used for quantification of IFN-g
production and was performed essentially as described
by Kuklin et al. (1997) and intracellular staining for
IFNg (ICG) was performed as described by Kumaraguru
and Rouse (2000) using the BD Bioscience Cytofix/
Cytoperm reagents. All antibodies used were purchased
from BD Bioscience (San Diego, CA). Double color
fluorescence analysis was performed using a FACScan
flow cytometer and CellQuest software.
Assessment of virus clearance
Mice were immunized with SSIEFARL/TLR9 ligand
and given rIL-12, pIL-15, or anti-CD40. Sixty days
later, mice were infected intraperitoneal with a recombi-
nant vaccinia virus encoding gB of HSV. Efficacy of
virus clearance in animals injected with rIL-12, pIL-15,
or anti-CD40 was determined on days 3 and 7 by
assessing the viral load in the ovaries of challenged
mice. A low dose (105 pfu) and a high dose (107 pfu)
were tested. Ovaries were collected, homogenized, clari-
fied in PBS, and used for virus titration in a viral pla-
que assay.
Statistical analysis
Appropriate significant differences were calculated with
Student’s t test. P values V0.05 were considered to be
statistically significant.Acknowledgment
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